#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention

Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or CV disease fail to reach target LDL-c levels even when given the maximum tolerated dose of conventional hypolipidemic treatment. For these patients, inclisiran—a small interfering RNA (siRNA) that lowers cholesterol—offers hope. In the following article, we present a model example of a patient after an acute coronary event for whom starting inclisiran treatment is appropriate.
Source: Chronic Heart Failure and Lipidology 23. 12. 2022

News Cenobamate −⁠ A Case Study from Slovak Real Practice

Cenobamate is indicated for adjunctive therapy of focal seizures with or without secondary generalization in adult patients who have not achieved sufficient results with previous treatment with at least 2 antiepileptics. This new anti-seizure medication with a dual mechanism of action thus brings another therapeutic option for patients refractory to treatment. At the November 34th Slovak-Czech Epileptology Congress in Bratislava, during a symposium titled “Is there hope for a quality life with epilepsy?” doc. MUDr. Eva Feketeová, PhD., from the Neurological Clinic LF UPJŠ and UNLP in Košice shared her first experiences with cenobamate in clinical practice.
Source: Epilepsy 23. 12. 2022

News Undiagnosed Hereditary Angioedema in Pregnancy –⁠ Case Study

Delayed diagnosis or misdiagnosis is not uncommon with hereditary angioedema (HAE), especially during pregnancy and the postpartum period. A case study by Canadian authors illustrates that HAE should be considered in the differential diagnosis for any patient with unexplained abdominal pain and recurrent swellings without the presence of urticaria.
Source: Hereditary Angioedema 8. 12. 2022

News Successful Long-Term Subcutaneous Prophylaxis of Hereditary Angioedema –⁠ Case Study

Hereditary angioedema (HAE), arising from a deficiency of C1 inhibitor (C1-INH), clinically manifests as swelling of the subcutaneous tissue and mucous membranes. The standard prophylactic therapy consists of intravenous (i.v.) substitution of C1-INH. We present a case study of successful long-term subcutaneous (s.c.) prophylaxis in a patient who had to discontinue i.v. prophylaxis.
Source: Hereditary Angioedema 8. 12. 2022

News Critical Conditions in Obstetrics 2022: What is Available in the Czech Republic for Managing Peripartum Life-Threatening Bleeding?

On December 10, 2022, a professional meeting entitled Critical Conditions in Obstetrics 2022 was held in the lecture hall of the new building of the National Museum in Prague. Prof. MUDr. Antonín Pařízek, CSc., from the Department of Gynecology and Obstetrics of the 1st Faculty of Medicine, Charles University, and General University Hospital in Prague, gave a presentation addressing the issue of peripartum life-threatening bleeding (PLTB), the necessities for its management, and provided an overall perspective on the current situation in obstetrics in our country.
Source: Postpartum Hemorrhage 14. 3. 2023

News Role of Transthyretin in the Development of Amyloidosis

Transthyretin (TTR), one of the transport proteins, tends to form extracellular deposits that accumulate in key organs, such as the heart and nerves. The formation of TTR deposits leads to the development of systemic amyloidosis, a disease with highly heterogeneous clinical manifestations. Warning signs may include carpal tunnel syndrome, among others. What is the physiological role of TTR in the body and what role does its structure play in the development of amyloidosis?
Source: Amyloidosis 20. 12. 2022

News Practical Experiences Using ZULP in Cardiology

The application of a product containing ferric carboxymaltose (FCM) or the use of a contrast agent with sulfur hexafluoride in microbubbles are examples of the use of specially accounted medicinal products (ZULP) in cardiology practice. "A benefit for the patient is that they receive the indicated preparation directly in the office and do not have to procure it themselves from a pharmacy," says Dr. Jiří Veselý, head physician of the Edumed cardiology clinic in Jaroměř, with whom we discussed the advantages and disadvantages of using ZULP and his experiences with this system.
Source: Chronic Heart Failure and Lipidology 12. 12. 2022

News How Will the New Player in Dyslipidemia Therapy Change the "Rules of the Game"?

Inclisiran, as an innovative drug indicated for adult patients with primary hypercholesterolemia or mixed dyslipidemia, was registered in the European Union at the end of 2020. Internists and cardiologists can now share their first experiences with this therapy in real practice. Case reports from the Czech Republic have also been published in specialized literature.
Source: Chronic Heart Failure and Lipidology 12. 12. 2022

News Impact of Administering Omega-3 Fatty Acids on the Risk of Metabolic Syndrome in Patients with Schizophrenia

The aim of the Polish clinical study OFFER was to assess the possibility of influencing the risk of developing metabolic syndrome (MetS) and some of its individual components in patients with first-episode schizophrenia by supplementing with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Source: Modern Treatment of Schizophrenia 13. 12. 2022

News Tool for Predicting Cardiometabolic Risk in Young Patients with Psychotic Disorder

A study describing the development and validation of an algorithm for predicting cardiometabolic risk in patients with psychotic disorder, PsyMetRiC (Psychosis Metabolic Risk Calculator), was recently published in Lancet Psychiatry. British scientists have created a tool to estimate the risk of developing metabolic syndrome over the next 6 years, serving as a predictor of cardiovascular morbidity and mortality in young people with psychosis aged 16–35 years.
Source: Modern Treatment of Schizophrenia 13. 12. 2022

News Viral or Bacterial Etiology? Old Question, New Methods...

The gold standard in the differential diagnosis of viral and bacterial respiratory infections is primarily C-reactive protein (CRP), followed by procalcitonin and interleukins. What are the pitfalls of their use, and what new methods of distinguishing the etiology of infectious diseases are currently being developed?
Source: Cough Therapy 13. 12. 2022

News Factors Predicting Longer Survival in Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil

A recently published non-interventional analysis evaluated overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) with favorable prognostic factors before initiating treatment with trifluridine/tipiracil compared to patients with unfavorable factors. It also identified which specific prognostic factors are favorable in terms of therapy effectiveness.
Source: Treatment of Gastrointestinal Carcinomas 14. 12. 2022

News Presence of Risk Factors Associated with Colectomy in Patients with Ulcerative Colitis in Studies with Tofacitinib

One of the important goals of active ulcerative colitis therapy is the prevention of colectomy. A clinical study, the results of which were recently presented at the Vienna UEG (United European Gastroenterology) congress, evaluated the association of risk factors and the use of tofacitinib with colectomy in patients with active ulcerative colitis in the OCTAVE clinical trial program.
Source: Intestinal Inflammations 4. 12. 2022

News What did the first data from the pilot lung cancer screening show?

Czech pulmonologists have released the first interim results of this year's pilot testing of heavy smokers due to the risk of lung cancer. More than 4,000 patients passed through the hands of general practitioners, and 900 subsequently underwent low-dose CT examination. What other specific findings emerge from the data collection? And what challenges do the experts involved in this program face?
Source: MDT Board 5. 12. 2022

News Pathogenetic Mechanisms Underlying the Development and Progression of Interstitial Lung Diseases

Interstitial lung processes (ILP) represent an umbrella term for a wide range of nosological units that differ from each other in clinical course, prognosis, and pathogenesis. Most ILPs are characterized by inflammation or fibrosis of the interstitial space, leading to impaired gas exchange at the alveolocapillary membrane.
Source: Progressive Interstitial Pulmonary Processes 6. 12. 2022

1 17 18 19 20 21 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#